이매틱스(IMTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.58 (-2.72%), 시가총액 $1.45B, 52주 최저~최고 $4.93 ~ $11.87.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's
이매틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이매틱스의 현재 주가는 $8.58 (-2.72%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이매틱스의 시가총액은 약 $1.45B입니다.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The